(Q48802606)

15 February 2018

title

Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. (English)

1 reference

15 February 2018

1 reference

Shuto H

1

1 reference

15 February 2018

Kataoka Y

2

1 reference

15 February 2018

Horikawa T

3

1 reference

15 February 2018

Fujihara N

4

1 reference

15 February 2018

Oishi R

5

1 reference

15 February 2018

language of work or name

English

0 references

publication date

1 February 1997

1 reference

15 February 2018

number of pages

4

1 reference

based on heuristic

inferred from page(s)

published in

Brain Research

1 reference

15 February 2018

volume

747

1 reference

15 February 2018

issue

2

1 reference

15 February 2018

page(s)

348-351

1 reference

15 February 2018

Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2896%2901371-6

Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2896%2901371-6

Human leukocyte interferon (HuIFN-alpha): potent endorphin-like opioid activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2896%2901371-6

7 January 2021

Dopamine and depression

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2896%2901371-6

Behavioral effects of mouse interferons-alpha and -gamma and human interferon-alpha in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2896%2901371-6

Does the immune system communicate with the central nervous system? Interferon modifies central nervous activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2896%2901371-6

Behavioural and ECoG spectrum changes induced by intracerebral infusion of interferons and interleukin 2 in rats are antagonized by naloxone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2896%2901371-6

The biological basis for clinical use of interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2896%2901371-6

Mechanisms of fever induced by recombinant human interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2896%2901371-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2896%2901371-6

Persistent neurotoxicity of systemically administered interferon-alpha.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2896%2901371-6

Interferons and their actions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2896%2901371-6

CSF amine metabolites in depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2896%2901371-6

Psychiatric complications of long-term interferon alfa therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2896%2901371-6

Central nervous system toxicity of interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2896%2901371-6

Reduced CSF concentrations of homovanillic acid and homovanillic acid to 5-hydroxyindoleacetic acid ratios in depressed patients: relationship to suicidal behavior and dexamethasone nonsuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2896%2901371-6

Cerebrospinal fluid monoamine metabolites and suicidal behavior in depressed patients. A 5-year follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2896%2901371-6

Marked reduction in indexes of dopamine metabolism among patients with depression who attempt suicide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2896%2901371-6

Neurological effects of recombinant human interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2896%2901371-6

Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2896%2901371-6

Monoamine metabolites in CSF and suicidal behavior

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2896%2901371-6

Interferons with Special Emphasis on the Immune System

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2896%2901371-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-8993(96)01371-6

1 reference

15 February 2018

PubMed ID

9046014

1 reference

15 February 2018